LungLife AI Inc Total Liabilities
LungLife AI Inc total liabilities. Based on the latest financial reports, LungLife AI Inc (LLAI) has total liabilities worth GBX1.13 Million GBX (≈ $137.00 USD) as of June 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check LungLife AI Inc (LLAI) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of LungLife AI Inc (2018–2023)
Total liabilities of LungLife AI Inc from 2018 to 2023. This chart illustrates how LungLife AI Inc's total liabilities have evolved over time, based on quarterly financial data.
LungLife AI Inc Competitors by Total Liabilities
The table below lists competitors of LungLife AI Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Worldsec Ltd
LSE:WSL
|
UK | GBX90.00K |
|
ECD Automotive Design Inc
NASDAQ:ECDA
|
USA | $25.89 Million |
|
Endor AG
MU:E2N
|
Germany | €124.10 Million |
|
Isaac Engineering Co. Ltd.
KQ:351330
|
Korea | ₩41.54 Billion |
|
MediaZest plc
LSE:MDZ
|
UK | GBX3.11 Million |
|
Ordinary Fully Paid Deferred Settlement
AU:BCNDA
|
Australia | AU$49.41 Million |
|
Eenergy Group PLC
LSE:EAAS
|
UK | GBX23.52 Million |
|
Distil Plc
LSE:DIS
|
UK | GBX951.00K |
Liability Composition Analysis (2018–2023)
This chart breaks down LungLife AI Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see LLAI total assets.
Liquidity & Leverage Metrics
LungLife AI Inc Total Liabilities Ratios Explained
LungLife AI Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.83 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.14 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.12 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how LungLife AI Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for LungLife AI Inc (2018–2023)
The table below shows the annual total liabilities of LungLife AI Inc from 2018 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | GBX1.61 Million ≈ $195.77 |
-14.41% |
| 2022-12-31 | GBX1.88 Million ≈ $228.74 |
+2.36% |
| 2021-12-31 | GBX1.84 Million ≈ $223.47 |
-7.87% |
| 2020-12-31 | GBX1.99 Million ≈ $242.55 |
-76.63% |
| 2019-12-31 | GBX8.53 Million ≈ $1.04K |
+123.22% |
| 2018-12-31 | GBX3.82 Million ≈ $464.98 |
-- |
About LungLife AI Inc
LungLife AI, Inc., a diagnostic company, researches and develops clinical diagnostic solutions for lung cancer with artificial intelligence (AI) technology in the United States and the People's Republic of China. The company engages in developing LungLB, a blood-based test to stratify cancerous and benign lung nodules identified by CT scan. The company was formerly known as Cynvenio Biosystems, I… Read more